Abstract
The current work highlights the preparation and antitumor activity of new benzimidazole derivatives of the natural product vanillin as a novel aromatase inhibitor. All the newly reported hybrids were characterized using sophisticated analytical techniques like NMR, IR, and mass spectrometry. The anticancer results against five cancer cell lines exhibited compounds 6, 7, and 8 to be most sensitive with IC50 in the range 0.36–8.65 μM, whereas doxorubicin showed IC50 of 4.74 μM and 3.69 μM toward breast cancer cells, MCF-7 and MDA-MB-231, respectively. Also, compound 6 revealed promising aromatase inhibition with IC50 0.064 μM while 7 and 8 with IC50 1.16 and 2.87 μM, respectively. Compound 9-bearing morpholine heterocycle revealed a better antibacterial effect on S. aureus with 22 mm (ZI) and MIC of 25 µg/disk than amoxicillin. These synthesized compounds displayed desirable pharmacokinetic properties and interacted with active sites of the aromatase enzyme in docking study. In conclusion, compound 6 was found to be a promising molecule as an aromatase inhibitor for breast cancer therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
